Clarke, Jeffrey M.
George, Daniel J.
Lisi, Stacey
Salama, April K. S.
Funding for this research was provided by:
AstraZeneca
Article History
First Online: 13 February 2018
Compliance with Ethical Standards
:
: Medical writing support was provided by Stephanie K. Doerner, PhD, Francesca Balordi, PhD, and Robert Schupp, PharmD, CMPP, of The Lockwood Group (Stamford, CT, USA), in accordance with Good Publication Practice (GPP3) guidelines, and was funded by AstraZeneca (Wilmington, DE, USA).
: Jeffrey Clarke has received grants from MedPacto, consulting fees from Inivata, and research support from Genentech, Bristol-Myers Squibb, and Adaptimmune Therapeutics. Daniel George has received research grant support from Acerta, AstraZeneca, and Millennium; consultancy fees from Acceleron Pharma and Merck; honoraria from BioPharm Communications/ClinTopicsSuperscript removed; research grant support and consultancy fees from Bristol-Myers Squibb, Exelixis, Genentech, Novartis, and Janssen Pharmaceuticals; consultancy and speaker bureau fees from Dendreon Corporation/Valeant; consultancy fees and compensation for participating on steering committees from Myovant Sciences; research grant support, consultancy fees, and honoraria from Astellas/Medivation; research grant support, consultancy fees, and speaker bureau fees from Bayer Healthcare Pharmaceuticals and Sanofi-Aventis; research grant support, consultancy fees, and compensation for participating on steering committees from Pfizer and Viamet/lnnocrin. The Duke Institutional Conflict of Interest Committee has determined that Dr. George has no restrictions on any of his Duke University-related activities based upon payment received from any of the sponsors listed above. April Salama has received payment for participation on advisory boards for Bristol-Myers Squibb and Merck and for serving as a speaker for Bristol-Myers Squibb. Dr. Salama’s research institution has received research grant support from Bristol-Myers Squibb, Celldex Therapeutics, Dynavax Technologies Corporation, Genentech, Immunocore, Merck, and Reata Pharmaceuticals. Stacey Lisi declares no conflict of interest.